AI treatment planning and case presentation (clearance status unverified)

Retrace is a dental AI company focused on treatment planning and case presentation. Unlike the dominant dental AI tools (Overjet, Pearl, VideaHealth), which center on radiograph analysis and pathology detection, Retrace targets the downstream workflow: helping dentists build treatment plans and present them to patients.

Important caveat on regulatory status: We have not been able to confirm FDA 510(k) clearance for Retrace as of February 2026. The product appears in various dental AI market listings and directories, but a search of public FDA databases did not return a confirmed clearance. This does not necessarily mean the product lacks clearance; it may operate under a classification that does not require 510(k) review, or clearance information may not yet be reflected in public records. Practices considering Retrace should verify its current regulatory status directly with the company before any clinical use.

Where Retrace fits in the market: Most dental AI investment and attention has gone toward diagnostic imaging: detecting caries, periapical pathology, and bone loss on radiographs. Treatment planning and case presentation is a less crowded category. If Retrace delivers on its stated focus, it could complement rather than compete with diagnostic AI platforms. That said, without verified FDA clearance and with limited publicly available clinical validation data, practices should approach evaluation with appropriate diligence. Start with FDA-cleared diagnostic tools if radiograph analysis is the priority, and evaluate Retrace separately for the treatment planning workflow after confirming its regulatory standing.